The Manila Times1h
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in ...
The American Journal of Managed Care4d
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...
Precision Medicine Online1d
Elevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces Workforce
The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
Yahoo Finance1d
Elevation Oncology, Inc. (ELEV)
After hours: March 25 at 7:59:47 PM EDT Loading Chart for ELEV ...